Insider · CIK 0001807437
Anirvan Ghosh
Files at UBX (Unity Biotechnology, Inc.). First filing Nov 6, 2024, latest Apr 3, 2025.
Anirvan Ghosh files SEC Form 4 as CEO and director at UBX (Unity Biotechnology, Inc.). Since Nov 6, 2024, Anirvan Ghosh has reported 0 open-market buys worth $0 and 3 open-market sells worth $102k, the latest filed on Apr 3, 2025.
A track record needs three past buys with six months of prices behind them; Anirvan Ghosh has 0, so none is measured yet.
The newest scored trade: sold $100k of UBX on Apr 2, 2025, filed Apr 3, 2025, scored 40 (moderate), under a 10b5-1 plan.
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Unity Biotechnology, Inc. | $100k 96,797 shares | -39% | - | |
| 5Weak | Unity Biotechnology, Inc. | $1,432 642 shares | -1% | - | |
| 20Weak | Unity Biotechnology, Inc. | $557 432 shares | -1% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Apr 3, 2025 | UBX UNITY BIOTECHNOLOGY, INC. | 96,797 63.08% of outstanding | $99k | Apr 2, 2025 | $1,432 |
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 2, 2025 | UBX Unity Biotechnology, Inc. | SOpen-market sale Common Stock, $0.0001 par value10b5-1 | -96,797 | $1.03 | $100k | 153,454 | Apr 3, 2025 |
| Mar 28, 2025 | UBX Unity Biotechnology, Inc. | AGrant or award Common Stock, $0.0001 par value | +175,000 | $0.00 | $0 | 250,251 | Mar 31, 2025 |
| Mar 28, 2025 | UBX Unity Biotechnology, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +286,000 | $0.00 | $0 | 286,000 | Mar 31, 2025 |
| Feb 4, 2025 | UBX Unity Biotechnology, Inc. | SOpen-market sale Common Stock, $0.0001 par value10b5-1 | -642 | $2.23 | $1,432 | 75,251 | Feb 5, 2025 |
| Jan 22, 2025 | UBX Unity Biotechnology, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +450,000 | $0.00 | $0 | 450,000 | Jan 23, 2025 |
| Nov 4, 2024 | UBX Unity Biotechnology, Inc. | SOpen-market sale Common Stock, $0.0001 par value10b5-1 | -432 | $1.29 | $557 | 75,893 | Nov 6, 2024 |
Questions about Anirvan Ghosh
Answered from the filings on this page, as of the latest one.
Is Anirvan Ghosh buying or selling?
Not in the last 12 months. Anirvan Ghosh's latest open-market trade on SEC Form 4 was sold $100k of UBX on Apr 2, 2025.
How did Anirvan Ghosh's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Anirvan Ghosh has 0.
Where does Anirvan Ghosh file Form 4?
Anirvan Ghosh has filed Form 4 at UBX (Unity Biotechnology, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.